guest ::
| Home > Publications database > Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. > print |
| Home > Publications database > Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. > print |
| 001 | 130700 | ||
| 005 | 20240228143455.0 | ||
| 024 | 7 | _ | |a 10.1038/mtm.2016.18 |2 doi |
| 024 | 7 | _ | |a pmid:27088104 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC4822647 |2 pmc |
| 024 | 7 | _ | |a altmetric:6509246 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-05778 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ungerechts, Guy |0 P:(DE-He78)833f90e2abdd29594ad5c4f08600f191 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. |
| 260 | _ | _ | |a New York, NY |c 2016 |b Nature Publishing Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1526373908_14604 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Oncolytic viruses (OVs) are unique anticancer agents based on their pleotropic modes of action, which include, besides viral tumor cell lysis, activation of antitumor immunity. A panel of diverse viruses, often genetically engineered, has advanced to clinical investigation, including phase 3 studies. This diversity of virotherapeutics not only offers interesting opportunities for the implementation of different therapeutic regimens but also poses challenges for clinical translation. Thus, manufacturing processes and regulatory approval paths need to be established for each OV individually. This review provides an overview of clinical-grade manufacturing procedures for OVs using six virus families as examples, and key challenges are discussed individually. For example, different virus features with respect to particle size, presence/absence of an envelope, and host species imply specific requirements for measures to ensure sterility, for handling, and for determination of appropriate animal models for toxicity testing, respectively. On the other hand, optimization of serum-free culture conditions, increasing virus yields, development of scalable purification strategies, and formulations guaranteeing long-term stability are challenges common to several if not all OVs. In light of the recent marketing approval of the first OV in the Western world, strategies for further upscaling OV manufacturing and optimizing product characterization will receive increasing attention. |
| 536 | _ | _ | |a 316 - Infections and cancer (POF3-316) |0 G:(DE-HGF)POF3-316 |c POF3-316 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Bossow, Sascha |b 1 |
| 700 | 1 | _ | |a Leuchs, Barbara |0 P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f |b 2 |u dkfz |
| 700 | 1 | _ | |a Holm, Per S |b 3 |
| 700 | 1 | _ | |a Rommelaere, Jean |0 P:(DE-He78)2d7958ea507b0b738619074b38ec6d54 |b 4 |u dkfz |
| 700 | 1 | _ | |a Coffey, Matt |b 5 |
| 700 | 1 | _ | |a Coffin, Rob |b 6 |
| 700 | 1 | _ | |a Bell, John |b 7 |
| 700 | 1 | _ | |a Nettelbeck, Dirk |0 P:(DE-He78)a074bc4fb40eed64043b5d34b4d6d523 |b 8 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1038/mtm.2016.18 |g Vol. 3, p. 16018 - |0 PERI:(DE-600)2863173-0 |p 16018 - |t Molecular therapy |v 3 |y 2016 |x 2329-0501 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:130700 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)833f90e2abdd29594ad5c4f08600f191 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)2d7958ea507b0b738619074b38ec6d54 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)a074bc4fb40eed64043b5d34b4d6d523 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-316 |2 G:(DE-HGF)POF3-300 |v Infections and cancer |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version) |0 LIC:(DE-HGF)CCBYNCNDNV |2 V:(DE-HGF) |b DOAJ |
| 920 | 1 | _ | |0 I:(DE-He78)G100-20160331 |k G100 |l Translationale Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F010-20160331 |k F010 |l Tumorvirologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)F110-20160331 |k F110 |l Onkolytische Adenoviren |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G100-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F010-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F110-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|